Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — H.C. Wainwright 26th Annual Global Investment Conference 2024
28 slides from Mayne Pharma's conference presentation, Sep 10, 2024
Slide 1: ASX Announcement: Mayne Pharma to present at H.C. Wainwright conference
ASX Announcement MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE 10 September 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C. Wainwri
Slide 2: Mayne Pharma Group Limited – HC Wainwright Conference
For personal use only Mayne Pharma Group Limited MYX.ASX HC Wainwright Conference September 10, 2024 Shawn Patrick O’Brien (CEO) Aaron Gray (CFO)
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market For personal use only disclosures. This material is not intended to be relied upon as advice to invest
Slide 4: Achieved all Key Operating Metrics in FY24
Achieved all Key Operating Metrics in FY241 Deliver positive direct Return Company to Return Company to Optimise cost base with NEXTSTELLIS® run rate For personal use only contribution in all three positive underlying positive operating cash reductions of >US$10m breakeven segments EBITDA3 in FY24 g
Slide 5: FY24 Financial Highlights
FY24 Financial Highlights1 Simplification of our business model combined with our strong operating and financial discipline has delivered significantly improved financial results For personal use only $388m 56.3% $22.9m Revenue Gross margin Underlying EBITDA2 up 112% FY23 up from 45.5% FY23 up from
Slide 6: FY24 Operating Highlights
FY24 Operating Highlights Women’s Health Dermatology International For personal use only • Completed asset purchase • Growth of NEXTSTELLIS®, oxycodone and • 3 new US FDA Orange-Book listed agreement to acquire the global UROREC® in Australia NEXTSTELLIS® patents expiring 2036 rights to RHOFADE® fro
Slide 7: FY24 Group Financial Performance
For personal use only FY24 Group Financial Performance
Slide 8: Group Continuing Operations Overview: Improved operational performance
Group Continuing Operations Overview1: Improved operational performance Change vs Change vs A$ million2 FY23 FY24 For personal use only FY23 ($) FY23 (%) Reported Revenue 183.6 388.4 204.8 112% Reported Gross Profit 83.5 218.8 135.3 162% Reported Direct Contribution (41.8) 88.5 130.3 312% Reported E
Slide 9: Improved cost leverage through growth and opex discipline
Improved cost leverage through growth and opex discipline (A$m) Segment Performance1 FY23 FY24 Change vs FY23 For personal use only (A$ million) FY24 Commentary Revenue 183.6 388.4 112% Gross Profit 83.5 218.8 162% • Cost containment measures executed in FY24 offset by Direct Operating Expenses (125
Slide 10: Segment Performance
For personal use only Segment Performance
Slide 11: Material Improvement in FY24 Direct Contribution
Material Improvement in FY24 Direct Contribution1 Benefit of scale and leverage starting to be demonstrated $88.5m For personal use only FY24 Total Direct Contribution FY23 Total Direct Contribution Dermatology ($21.0m) $9.0m Women’s Health ($27.7m) ($41.8m) +$130.3m International $6.9m $35.2m $44.3
Slide 12: Segment Performance
Segment Performance Refocused business delivering improved momentum and positive direct contribution in FY24 For personal use only Change Change Reported results (A$million) 2HFY23 1HFY24 2HFY24 FY23 FY24 vs FY23 2HFY23 1HFY24 2HFY24 FY23 FY24 vs FY23 1 Revenue Gross profit Dermatology 45.8 80.9 93.
Slide 13: Women's Health
For personal use only Women’s Health
Slide 14: Women's Health – favourable macro trends position Mayne Pharma well
Women’s Health – favourable macro trends positions Mayne Pharma well Key macro trends in Women’s Health Mayne Pharma For personal use only • Global menopause market hit US$15.4bn in 2021 and is • BIJUVA® – only available, FDA approved bioidentical projected to reach US$24.4bn by 20301 combination tr
Slide 15: Women's Health: Strong NEXTSTELLIS growth & full year impact of licensed portfolio
Women’s Health: Strong NEXTSTELLIS® growth & full year impact of licensed portfolio For personal use only FY24 Commentary • FY24 revenue up US$52m (125%) compared to FY23 Women's Health in US$'000 2HFY23 1HFY24 2HFY24 FY23 FY24 Total Revenue 32,667 47,277 46,361 41,671 93,638 • Revenue increase (FY2
Slide 16: Women's Health: revenue, margin and contribution summary
Women’s Health: revenue, margin and contribution summary 1HFY24 Total Revenue US$47.3m 2HFY24 Total Revenue US$46.4m For personal use only 2HFY23 Total Revenue US$32.7m +44.6% v 2HFY23 +41.9% v pcp, -2% seq. $2.0, 4% $2.3, 5% $2.2, 7% $5.0, 11% $4.5, 10% $2.9, 9% $13.8, 29% $7.1, 22% $16.3, 35% $8.5
Slide 17: NEXTSTELLIS demand cycles up 85%
NEXTSTELLIS® demand cycles1 up 85% NEXTSTELLIS® Quarterly US Demand Cycles (thousands) NEXTSTELLIS ® Net Sales (US$m) and growth (pcp) For personal use only 35.0 10.4% 113% 138 100.0% 30.1 5.9% 30.0 140.0 11.3% 90.0% 125 19.1% 118 120.0 80.0% 25.0 25.4% 106 70.0% 100.0 22.4% 89 20.0 60.0% 236% 80.0
Slide 18: Driving demand with IMVEXXY and BIJUVA for menopausal patients
Driving demand with IMVEXXY and BIJUVA for menopausal patients Licensed Portfolio Demand TRx (thousands)1 For personal use only IMVEXXY® BIJUVA® ANNOVERA® 350 120 306 98 30 28 27 300 100 26 250 225 76 25 213 80 68 20 200 60 15 150 40 100 10 50 20 5 - - - FY22 FY23 FY24 FY22 FY23 FY24 FY22 FY23 FY24
Slide 19: Dermatology
For personal use only Dermatology
Slide 20: Dermatology: Mayne Pharma can fill in retail Rx for med-derm
Dermatology: Mayne Pharma can fill 1 in 3 retail Rx for med-derm1 Key Macro trends in Dermatology Mayne Pharma For personal use only • Rising incidence of skin diseases, and a growing awareness • Increasing number of patients are treatable via Mayne and increased spend on personal care (e.g. Acne –
Slide 21: Dermatology: Delivering on new product launches and channel strategy
Dermatology: Delivering on new product launches and channel strategy For personal use only FY24 Commentary Dermatology in US$'000 2HFY23 1HFY24 2HFY24 FY23 FY24 Total Revenue 30,878 52,855 61,782 38,373 114,637 • FY24 revenue up US$76.3m (199%) compared to FY23 Total Gross Profit 10,226 23,908 31,11
Slide 22: Strong revenue, margin and contribution growth in Dermatology
Strong revenue, margin and contribution growth in Dermatology FY23 Revenue by Category – TOTAL US$38.4 million FY24 Revenue by Category – TOTAL US$114.6 million For personal use only $4.5, 12% $22.8, 20% Total Growth: 199% $33.9, 88% Growth Drivers $91.8, 80% Top 5 Products All Other RHOFADE® gACCUT
Slide 23: Dermatology – channel strategy / full disintermediation
Dermatology – channel strategy / full disintermediation Network Ecosystem Disintermediation Mayne Pharma is leveraging the inefficiencies Involves removing the intermediary For personal use only in the dermatology value chain through new (wholesaler) between the manufacturer partnerships aimed at im
Slide 24: International
For personal use only International
Slide 25: International: Strategic and operational levers building momentum
International: Strategic and operational levers building momentum For personal use only FY24 Commentary International in A$'000 2HFY23 1HFY24 2HFY24 FY23 FY24 Reported Revenue 37,079 34,608 36,105 64,704 70,713 Reported Gross Profit 10,048 10,480 10,902 18,924 21,382 • FY24 revenue up $6m (9%) compa
Slide 26: Outlook
For personal use only Outlook
Slide 27: FY25 outlook and focus
FY25 outlook and focus The Company expects to improve shareholder value with growth in underlying EBITDA in FY25 via revenue growth and cost leverage, with all three segments contributing positive direct contribution For personal use only Women’s Health Dermatology International Deliver profit poten
Slide 28: Q&A
Q&A For personal use only For further information contact: Australia: Dr Tom Duthy +61 402 493 727 ir@maynepharma.com US: Lisa M. Wilson +1 917-543-9932 ir@maynepharma.com You deserve tomorrow. 27
Mayne Pharma Group — H.C. Wainwright 26th Annual Global Investment Conference 2024 on 6ix